Technology

Ovation.io and PD Theranostics (PDTx) Complete Merger Creating a Multiomic Data Company Which Owns a Unique Population-Scale Biobank of Disease-Specific Biospecimens

Published

2 years ago

September 5, 2024

Ovation owns a unique population-scale biobank of consented and linkable disease-specific biospecimens, which includes more than 1.6 million samples from over 600,000 United States-based patients; approximately one-third are tissue samples. Ovation plans to continue expanding the biobank with the addition of 200,000 + patient samples per monthOvation’s biobank includes tissue, blood, and other sample types from patients with diseases of current discovery and development interest including inflammatory bowel disease (IBD), liver disease, chronic kidney disease (CKD), cardio-metabolic/GLP-1, various types of cancers, and neurodegenerative diseases such as Alzheimer’s diseaseThe Company plans to produce a database of linked omics and patient/clinical data for each diseaseThe merger combines teams with deep domain expertise in human genetics, disease pathogenesis, and pathology

PORTLAND, Maine and BOSTON, Sept. 5, 2024 /PRNewswire/ — Ovation.io and PDTx today announced the completion of their merger. The new entity creates an industry-leading multiomics data company managed by a team with deep expertise in genomics data, sequencing, bioinformatics, cell biology, and imaging, AI/ML and data commercialization. The Company’s enhanced platform capabilities and data libraries can drive deeper insights into cellular biology and gene expression for research, drug development, and clinical decision-making, and across a broad range of diseases.

“We believe the two companies are deeply complementary and will provide our customers with best-in-class, diverse multiomics data,” said Curt Medeiros, CEO of Ovation. “These one-of-a-kind data sets will combine Ovation’s DNA and RNA sequencing of patient samples in a given disease state with PDTx’s mapping of cellular footprints, spatial context, immune system functionality and markers, as well as clinical pathology imaging. This will help drive our client’s R&D efforts, from target and biomarker discovery, through optimized clinical trial enrollment.”

Human genomic data has become an increasingly important tool in disease target and biomarker discovery. By analyzing an individual’s genetic makeup, especially in relation to clinical progression and outcomes, researchers are able to better understand the underlying causes of diseases and identify potential therapeutic targets and biomarkers. Ovation is building the world’s broadest commercially available human genomic dataset that brings together whole genome sequences with longitudinal clinical records at the patient level (“clinic-genomics data”) to address the speed and cost at which new research efforts can be powered by human genomics. This clinic-genomics database will enable a depth and breadth of analytics not currently possible due to the scale, continuous flow of new patient samples, and diversity of patients.

“The Ovation and PDTx teams are energized and have been collaborating for the past year to position our first proof-of-concept programs in IBD and prostate cancer for groundbreaking results,” said Patrick Gallagher, CEO of PDTx. “The in-house biobank will allow the team to accelerate data generation and more fully leverage the PDTx platform’s high dimensional, multiomic modalities that characterize cellular status. This includes changes in and predictiveness of proteins, glycans, metabolites and cell-cell spatial relationships that can drive discovery and correlations with pathological features of disease severity, progression and therapeutic response.”

PDTx has developed a disease-agnostic platform to analyze data collected across multiple high-dimensional imaging technologies to discover new drug development targets and identify critical biomarkers of disease progression and therapeutic response. The PDTx platform provides the ability to visualize the presence, concentration, and distribution of molecules and analyze intra- and inter-molecular and phenotypic single-cell relationships and their impact on morphology. Ovation will retain PDTx’s exclusive global license for the platform and its intellectual property from Massachusetts General Hospital (MGH) and the Vaccine and Immunotherapy Center (VIC) at (MGH).

“Ovation’s ability to continuously scale its biobank and data to expand its curated disease cohorts that are representative of racial and geographic diversity in the United States is completely novel,” noted Mike Self, co-founder of StageDotO Ventures. “Linking this with longitudinal patient data creates a totally unique product that will allow for more targeted and efficient investment in development programs for our clients.”

By combining imaging and sequencing, state-of-the-art multiomics can map the location of specific proteins and chemical products in tissues and identify the location of presence of these chemical entities. This provides a critical perspective about the cellular microenvironment and inter-cellular interactions in biopsies of diseased tissue.

“We are incredibly excited to collaborate with the research team at Ovation,” said Mark Poznansky, M.D., Ph.D, director of the Vaccine and Immunotherapy Center at Massachusetts General Hospital. ” Connecting genetic data with cellular, structural and chemical details of tissue affected by IBD or prostate cancer can lead to important translational medical progress. For example, our combining a multiomics platform that provides information on both the genetic and protein signature in blood as well the location of specific chemicals and cells within a tissue, can help identify new sets of biomarkers that are potentially impactful diagnostically and prognostically as well as revealing of new disease related therapeutic targets.”

About Ovation
Ovation is an omics data company committed to accelerating the development of precision medicine. Ovation provides life sciences R&D teams access to high-quality omics data linked to rich, longitudinal clinical data, across therapeutic areas, at population scale. Ovation’s data increases the probability of success for drug discovery by enabling the identification and validation of biomarkers and therapeutic targets. The company has an extensive biobank of more than 1.6 million geographically diverse, consented biospecimens from over 625,000 unique patients. For more information, visit www.ovation.io or follow the company on LinkedIn.

About PD Theranostics
PDTx is a data driven healthcare company focused on leveraging proprietary workflows and using multi parameter imaging-based methodologies to generate robust, one-of-a-kind multi-omic cellular biology based databases for numerous disease states. Our proprietary imaging processes, driven by a multi-omics approach, will generate spatial roadmaps of human cancers and other diseases, leading to unparalleled data richness and depth. Through our ability to map tissue structures and immune populations, we believe we could more clearly define disease stage, and likelihood of disease progression, and identify the most efficacious treatment regimens for each patient.

Contact Information
Info@ovation.io

Forward-Looking Statement
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the Ovation Platform and other information that is not historical information. When used herein, words such as “anticipate”, “being”, “will”, “plan”, “may”, “continue”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based on Ovation’s current expectations and various assumptions. Ovation believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Ovation may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions. Consequently, forward-looking statements should be regarded solely as Ovation’s current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Ovation cannot guarantee future results, events, levels of activity, performance or achievements. Ovation does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ovationio-and-pd-theranostics-pdtx-complete-merger-creating-a-multiomic-data-company-which-owns-a-unique-population-scale-biobank-of-disease-specific-biospecimens-302239632.html

SOURCE Ovation.io

Technology

Hexagon releases new targets at its Capital Markets Day 2026

Published

3 hours ago

April 30, 2026

Hexagon is the global leader in precision measurement, positioning and autonomous solutions with a serviceable addressable market of ~€38bn by 2030.Hexagon’s €3.7bn in revenue and ~17,000 employees are across three Business Areas – Manufacturing Intelligence, Infrastructure & Especial and Autonomous Solutions plus a Robotics Division currently in an investment phase.Recent portfolio actions, including the upcoming separation of Octave, the sale of the Design & Engineering business and the announced acquisition of Agate Technologies, have focused Hexagon on its strong core business in precision measurement & positioning technologies.Hexagon’s organic growth will be driven by strong end market potential and structural tailwinds, new product introductions and an operating model focused on accountability and closeness to customers.Hexagon launches new financial targets for the 2026 – 2030 period of average organic revenue growth of 4-6%, an EBITDA margin of 24-26%[1] and an EBITDA cash conversion of 90-100%. It also targets reducing Scope 1 & 2 emissions by 70% by 2030, from a 2022 baseline.

[1] EBITAC is defined as adjusted EBIT1 excluding capitalised and amortised R&D. See pages the appendix for further information

STOCKHOLM, April 30, 2026 /PRNewswire/ — Hexagon AB is hosting its Capital Markets Day today in London. At the event, President and CEO Anders Svensson, CFO Enrique Patrickson and the Presidents of Hexagon’s Business Areas will set out Hexagon’s ambitious growth strategy and its new 2026–2030 financial targets.

“Hexagon enters this new phase as a focused global leader in precision measurement and positioning, with a solutions portfolio essential to enabling industrial autonomy,” said Anders Svensson, President and CEO of Hexagon. “Our new targets reflect both the quality of our portfolio and the discipline of The Hexagon Way. With a strong leadership team and the financial flexibility to invest behind our growth priorities both organically and through synergistic acquisitions, we are well placed to deliver value creation for shareholders.”

“Today we are taking transparency to the next level — enhancing our disclosures, introducing EBITAC as our key profitability metric and providing clarity around our capital allocation priorities,” said Enrique Patrickson, CFO of Hexagon. “EBITAC is the right metric for Hexagon, a technology company with a significant R&D spend, funding market-leading product launches that drive our growth. With additional transparency comes additional accountability. We commit to drive capital allocation around R&D, M&A and Dividends with discipline and rigor.”

New sustainability targets

70% reduction in Scope 1 & 2 emissions by 2030 (from 2022 baseline)Net-zero by 2050

New 2026–2030 financial targets

Average annual organic revenue growth of 4-6%EBITAC margin in the range of 24-26%Annual cash conversion (of EBITAC) of 90-100%

A focused group focused on enabling industrial autonomy

Hexagon has undertaken significant portfolio changes, namely the upcoming spin-off of Octave and the sale of the Design & Engineering business. The resulting business is a focused global leader in precision measurement and positioning with proforma 2025 revenue of €3.7bn, EBITAC of €826m (22% EBITAC margin) and ~17,000 employees.

Hexagon is organised into three business areas – Manufacturing Intelligence, Infrastructure & Geospatial (formerly Geosystems) and Autonomous Solutions – alongside the Robotics Division, currently in an investment phase.

The overarching growth opportunity that underpins Hexagon’s long-term strategy is enabling customers to move towards true autonomy in their industrial operations.

President and CEO Anders Svensson will outline how Hexagon’s precision measurement and positioning technologies, digital twins and spatial intelligence capabilities are essential to enabling this true industrial autonomy. Hexagon holds market leadership positions across its serviceable addressable market, which is estimated to grow to ~€38bn by 2030.

Anders will also outline the key changes to Hexagon’s operating model. The Hexagon Way is an accountability-driven, decentralised model built around three strategic enablers: innovation and AI; portfolio management and M&A; and people & culture.

Central to this model is a clear accountability structure: the group’s three Business Areas are divided into 17 Divisions, each with full ownership of its financial performance and a defined strategic mandate covering three value creation priorities – Stability, Profitability and Growth.

The group-wide enablers allow Divisions to identify and execute on strategies targeted specifically to their markets and customers while drawing on the scale and resources of the broader Hexagon organisation. This balance of focused execution at the Division level and shared capability at the group level is designed to unlock each Division’s full potential and drive overall performance and shareholder value.

Hexagon’s new mid-term financial targets for 2026 to 2030 will be outlined by CFO Enrique Patrickson alongside a new financial framework including revised metric definitions designed to improve transparency, capital allocation and shareholder value creation.

The new 2026-30 through the cycle targets are:

Average annual organic revenue growth of 4–6% (CAGR 2026–2030)EBITAC margin in the range of 24–26%Annual cash conversion (of EBITAC) of 90–100%

In 2025, Hexagon achieved organic growth of 2.6%, an EBITAC margin of 22% and cash conversion (of EBITAC) of 109%.

Capital allocation

Hexagon’s capital allocation priorities are, in order: reinvestment in organic growth, value-accretive bolt-on M&A, a progressive dividend, and selective larger strategic moves where they enhance long-term shareholder value. The Group’s strong cash conversion and balance sheet provide the flexibility to pursue these priorities through the cycle.

Business Area presentations

Senior leadership from Hexagon’s Business Areas will provide additional context on strategy, markets and Business Area targets. The presenters will be:

Andreas Renulf, President, Manufacturing Intelligence Business AreaHenning Sandfort, President, Infrastructure & Geospatial Business AreaGordon Dale, President, Autonomous Solutions Business AreaArnaud Robert, President, Robotics Division

EBITAC – EBIT1 excluding capitalisation & amortisation of R&D

Hexagon is introducing EBITAC as its primary profitability measure. By immediately reflecting the full cost of R&D investments on the P&L, it will provide a tool to focus management firmly on the return on investment of R&D, go-to-market and capital investments and support performance management and capital allocation. The top end of the target EBITAC margin range (26%) was last achieved in 2021 and corresponds to the highest EBIT1 margin achieved by Hexagon in the last 5-years.

It is defined as adjusted EBIT1 excluding capitalised and amortised R&D.

Hexagon will continue to report EBIT1 (adjusted operating profit) for full transparency. A bridge between reported EBIT, EBIT1 and EBITAC and the EBITAC performance between 2024 and 2025 can be found in the appendix to this announcement.

Profitability metric bridge, 2025

Item

€M

Reported EBIT

575

Add: in year adjustments (impairments, restructuring, LTIP, PPA)

+372

EBIT1

947

Subtract: R&D capitalisation

-340

Add: R&D amortisation

+195

EBITAC

802

Subtract: in year robotics costs

+24

EBITAC (target definition)

826

Robotics – AEON, a potential global market leader in humanoid Robotics

Investment in Robotics to double from €24m in 2025 to €50m in 2026.Pilots with BMW, Schaeffler, Pilatus & Fill underway.Robotics is an exciting opportunity for significant value creation.

Due to its rapidly evolving structure Hexagon has decided to exclude Robotics from the 2026-30 financial targets and the calculation of EBITAC. This gives better visibility on the core group performance.

The financial performance of Robotics will be disclosed on a quarterly basis.

New sustainability targets

Hexagon is committed to operating responsibly for the good of the environment. It has set challenging new targets for emission reductions. Hexagon targets a 70% reduction in Scope 1 & 2 emissions by 2030 (from a 2022 baseline) and net-zero in Scope 1, 2 & 3 by 2050.

In 2025 Hexagon saw a 33% reduction in Scope 1 & 2 emissions from its 2022 baseline.

Joining instructions

The webcast will be streamed here: https://edge.media-server.com/mmc/p/d2han2qw/

FOR MORE INFORMATION, CONTACT:
Tom Hull, Head of Investor Relations, Hexagon AB, +44 7442 678 437, ir@hexagon.com
Anton Heikenström, Investor Relations Manager, Hexagon AB, +46 8 601 26 26, ir@hexagon.com

This is information that Hexagon AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on 30 April 2026.

Appendix – Reconciling EBIT1 & EBITAC performance, 2025 quarterly

Metric

Q1 2025

Q2 2025

Q3 2025

Q4 2025

FY 2025

Revenue €m

961.5

1,010.5

976.0

1,053.1

4,001.2

EBIT1 €m

248.7

260.0

264.7

299.1

1,072.4

Subtract: capitalisation of R&D €m

-94.6

-94.7

-91.1

-84.1

-364.5

Add: amortisation of R&D €m

54.6

54.3

59.2

50.4

218.5

EBITAC €m

208.7

219.6

232.8

265.3

926.4

In year robotics cost €mEBIT

-4.7

-5.9

-5.6

-7.6

-23.7

EBITAC (excluding robotics costs)

213.4

225.5

238.3

272.9

950.1

EBIT1 margin %

25.9 %

25.7 %

27.1 %

28.4 %

26.8 %

EBITAC margin %

21.7 %

23.8 %

25.2 %

23.2 %

EBITAC margin % (excluding robotics costs)

22.2 %

22.3 %

24.4 %

25.9 %

23.7 %

Appendix – Reconciling EBIT1 & EBITAC performance, 2025 quarterly, excluding Design & Engineering

Metric

Q1 2025

Q2 2025

Q3 2025

Q4 2025

FY 2025

Revenue €m

888.2

939.4

907.1

980.3

3,715.0

EBIT1 €m

225.0

231.1

235.5

255.4

947.0

Subtract: capitalisation of R&D €m

-88.6

-88.0

-84.8

-78.3

-339.6

Add: amortisation of R&D €m

48.2

48.0

53.3

45.8

195.3

EBITAC €m

184.6

191.1

204.0

223.0

802.7

In year robotics cost €m

-4.7

-5.9

-5.6

-7.6

-23.7

EBITAC (excluding robotics costs)

189.3

196.9

209.6

230.5

826.4

EBIT1 margin %

25.3 %

24.6 %

26.0 %

26.1 %

25.5 %

EBITAC margin %

20.8 %

20.3 %

22.5 %

22.7 %

21.6 %

EBITAC margin % (excluding robotics costs)

21.3 %

21.0 %

23.1 %

23.5 %

22.2 %

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/hexagon/r/hexagon-releases-new-targets-at-its-capital-markets-day-2026,c4342580

The following files are available for download:

https://mb.cision.com/Main/387/4342580/4069574.pdf

Hexagon releases new targets at its Capital Markets Day 2026

View original content:https://www.prnewswire.com/news-releases/hexagon-releases-new-targets-at-its-capital-markets-day-2026-302758483.html

SOURCE Hexagon

Technology

Accountants Streamline Cash Flow with ezACH Direct Deposit Software

Published

3 hours ago

April 30, 2026

Eliminate payment delays, reduce manual errors, and gain full control with a low-cost and high-quality ACH solution built for modern accounting workflows.

REDMOND, Wash., April 30, 2026 /PRNewswire/ — Halfpricesoft.com developers understand that businesses demand faster payments and greater financial control, and now accountants are rethinking how they manage transactions. ezACH direct deposit software will simplify payment processing, accelerate cash flow, and reduce costly errors.

Clients are encouraged to download and test ezACH today to purchase to confirm compatibility.

ezACH empowers accountants to securely process electronic payments for clients, vendors, payroll, and tax obligations, all from one streamlined platform. By generating ACH files that can be uploaded directly to a bank, the software removes the need for manual payment handling and outdated processes.

“Speed and accuracy are critical in today’s financial environment,” said Dr. Ge, Founder of Halfpricesoft.com. “ezACH gives accountants the ability to process multiple payments quickly and securely, without added complexity or cost.”

Designed with flexibility in mind, ezACH allows users to manage unlimited transactions for unlimited companies at a one-time flat rate of $199.00, making it a cost-effective alternative to subscription-based payment platforms. Try it today!

Why Accountants Are Making the Switch:

Process ACH payments for vendors, clients, payroll, and tax agenciesEliminate manual entry and reduce costly errorsImport data easily from CSV files or other Halfpricesoft applicationsHandle unlimited companies and transactions with no recurring feesMaintain full control over payment timing and processingClients can upload transactions for up to $4.99 to test compatibility

Halfpricesoft.com offers a variety of applications that will seamlessly integrate with ezACH software:

ezPaycheck: A new version of ezACH has just been released to support import CSV with ezPaycheck importing. ezCheckprinting: Business check writer for vendors, miscellaneous and draft checks. https://www.halfpricesoft.com/product_ezCheck.aspezAccounting: DIY in-house bookkeeping and payroll solution for one flat rate. https://www.halfpricesoft.com/accounting/accounting-software.asp

With a one-time cost of $199 per installation, ezACH offers long-term savings compared to subscription-based services. There are no hidden fees, and users can process unlimited ACH transactions. (Note: Banks may apply their own ACH processing fees. We recommend contacting your bank for compatibility prior to purchase).

Simplify the business operations and boost efficiency with the powerful, all-in-one solutions fromHalfpricesoft.com. To save both time and money, get started today at HalfPriceSoft.com for no cost or obligation

About Halfpricesoft.com

Halfpricesoft.com has been delivering affordable, reliable business software solutions for over 20 years. Its suite of products, including payroll, accounting, check printing, tax filing, and ACH deposit software, helps small businesses, accountants, and nonprofits streamline operations and reduce costs. Trusted by thousands nationwide, Halfpricesoft.com remains committed to simplifying financial management with powerful, budget-friendly tools.

View original content to download multimedia:https://www.prnewswire.com/news-releases/accountants-streamline-cash-flow-with-ezach-direct-deposit-software-302739456.html

SOURCE Halfpricesoft.com

Technology

Neusoft Smart Go and Tencent Cloud Forge Strategic Partnership to Build a New AI-Powered Intelligent Cockpit Ecosystem

Published

3 hours ago

April 30, 2026

BEIJING, April 30, 2026 /PRNewswire/ — At Auto China 2026, Neusoft Smart Go, a subsidiary of Neusoft Corporation (SSE:600718), officially announced its strategic upgrade. The company now aims to become a global leading provider in full-domain upper-body electronics solutions for intelligent vehicles. At the same time, Neusoft Smart Go and Tencent Cloud announced a strategic partnership. Aligning with “AI-defined vehicles” trend, the two parties will focus on key areas such as intelligent cockpits, on-device AI large model applications, ecosystem content integration, in-vehicle cybersecurity, and cloud services. By integrating their technologies and resources, they will engage in in-depth collaboration to develop AI-powered intelligent cockpit products and solutions that offer enhanced interactivity and emotional experiences, accelerating the intelligent transformation of entire vehicles.

The integration of AI large models and ecosystems into vehicles is essentially a full-chain systematic project covering hardware-software architecture adaptation, data processing, compliance assurance, and real-time response. Currently, automakers face challenges such as high in-house R&D expenses, ecosystem integration hurdles, and a lack of differentiated user experiences. They urgently require full-domain solutions that seamlessly integrate hardware and software, offer comprehensive ecosystem coverage, and enable rapid mass production to meet users’ core demands for multi-modal interaction, full-scenario services, and continuous OTA updates.

As a leading cloud service provider in China, Tencent Cloud has core strengths in on-device large models, in-vehicle ecosystems and applications, cloud services, and data compliance assurance. It also offers a full-chain app ecosystem spanning social media, music, maps, and more. In this partnership, the two parties will take Neusoft Smart Go’s next-gen intelligent cockpit system as the core platform, deeply integrating Tencent Cloud’s on-device large models to jointly develop a benchmark AI-powered intelligent cockpit featuring natural conversations, proactive interactions, and highly emotional, smooth experiences. Furthermore, they will fully integrate a wide range of ecosystem apps, enabling seamless transitions between mobile phones and in-vehicle systems across all scenarios.

At present, Neusoft Smart Go has established a product matrix covering a full range of in-vehicle electronics solutions, including central computing platforms, cockpit-driving-parking integration, intelligent cockpits, intelligent communications, intelligent audio systems, and zonal control units. Through a dual-track strategy of high-end cutting-edge solutions and mature standardized products, it can flexibly meet the mass production needs of vehicle models across different regions and price segments worldwide. Leveraging Tencent’s intelligent driving cloud, data compliance, OTA technical support, and AI platform services, the two parties will provide stable, secure, and intelligent hardware-software integrated solutions tailored to the diverse needs of global automakers, comprehensively assisting them in achieving intelligent and AI-driven upgrades for entire vehicles.

Jian Guodong, Senior Vice President of Neusoft and CEO of Neusoft Smart Go, said, “The integration of AI large models and full-scenario ecosystems represents an inevitable trend and a shared vision for both Neusoft Smart Go and Tencent Intelligent Mobility. Leveraging Neusoft Smart Go’s technical expertise in the full domain of upper-body electronics and Tencent’s leading solutions in AI large models and full-chain ecosystems, the two parties will collaborate to provide global automakers with truly mass-producible and evolvable AI-powered intelligent cockpit solutions.”

Zhong Xuedan, Vice President and Head of Tencent Intelligent Mobility, said, “We share complementary strengths and similar philosophies with Neusoft Smart Go, laying a solid foundation for cooperation. Both parties will further deepen cooperation in AI-powered intelligent cockpits, jointly exploring proactive interactions and emotional services powered by large models, transforming the cockpit into a smarter companion that better understands users.”

The deep integration of on-device AI large models and full-scenario ecosystems is reshaping the value boundaries and user experiences of intelligent cockpits. The automotive industry needs to accelerate innovation and mass production, achieving a balance between advanced technologies and cost-effectiveness. Neusoft Smart Go will focus on enhancing its systematic integration, software-hardware synergy, and global delivery capabilities. Through collaboration with more ecosystem partners, it will provide sustained momentum for the intelligent transformation of the automotive industry.

View original content:https://www.prnewswire.com/news-releases/neusoft-smart-go-and-tencent-cloud-forge-strategic-partnership-to-build-a-new-ai-powered-intelligent-cockpit-ecosystem-302758495.html

SOURCE Neusoft Corporation